
    
      A multi-center, prospective single arm study to assess the efficacy and safety of retisert
      (intravitreal flucinolone acetonide 0.59 mg) in patients with refractory ocular Behcet's
      disease. This study will be conducted at 4 sites, located in Korea. The number of subject is
      expected approximately 15 patients. The medical records for the patients meeting following
      inclusion/exclusion criteria will be collected until 1 year after implantation.
    
  